Dehydroepiandrosterone (DHEA)

Encyclopedia of Dietary Supplements

Volumn , Issue , 2004, Pages 167-176

  Alesci, Salvatore ^a   Manoli, Irini ^b   Blackman, Marc R ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b National Institutes of Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955715818     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1081/E-EDS-120022909     Document Type: Chapter

References (53)

1. Vermeulen, A., Androgen secretion after age 50 in both sexes. Horm. Res. 1983, 18 (1–3), 37–42.
2. Baulieu, E.E.; Robel, P., Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc. Natl. Acad. Sci. U.S.A 1998, 95 (8), 4089–4091.
3. Alesci, S.; Bornstein, S.R., Neuroimmunoregulation of androgens in the adrenal gland and the skin. Horm. Res. 2000, 54 (5–6), 281–286.
4. Labrie, F.; Luu-The, V.; Labrie, C.; Pelletier, G.; El-Alfy, M., Intracrinology and the skin. Horm. Res. 2000, 54 (5–6), 218–229.
5. Alesci, S.; Bornstein, S.R. Intraadrenal mechanisms of DHEA regulation: a hypothesis for adrenopause. Exp. Clin. Endocrinol. Diabetes 2001, 109 (2), 75–82.
6. Parker, L.N.; Sack, J.; Fisher, D.A.; Odell, W.D. The adrenarche: prolactin, gonadotropins, adrenal androgens, and cortisol. J. Clin. Endocrinol. Metab. 1978, 46 (3), 396–401.
7. Blackman, M.R.; Elahi, D.; Harman, S.M., Endocrinology and aging. In Endocrinology, 3rd Ed.; DeGroot, L., Ed.; W.B. Saunders Co.: Philadelphia, 1995, Chapter 147; 2702–2730.
8. Labrie, F.; Belanger, A.; Cusan, L.; Gomez, J.L.; Candas, B., Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab 1997, 82 (8), 2396–2402.
9. Klein, H.; Bressel, M.; Kastendieck, H.; Voigt, K.D. Quantitative assessment of endogenous testicular and adrenal sex steroids and of steroid metabolizing enzymes in untreated human prostatic cancerous tissue. J. Steroid Biochem. 1988, 30 (1–6), 119–130.
10. Rupprecht, R.; Holsboer, F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 1999, 22 (9), 410–416.
11. Schwartz, A.G.; Pashko, L.L. Mechanism of cancer preventive action of DHEA. Role of glucose-6-phosphate dehydrogenase. Ann. N. Y. Acad. Sci. 1995, 774, 180–186.
12. Casson, P.R.; Straughn, A.B.; Umstot, E.S.; Abraham, G.E.; Carson, S.A.; Buster, J.E. Delivery of dehydroepiandrosterone to premenopausal women: effects of micronization and nonoral administration. Am. J. Obstet. Gynecol. 1996, 174 (2), 649–653.
13. Robel, P.; Baulieu, E.E. Dehydroepiandrosterone (DHEA) is a neuroactive neurosteroid. Ann. N. Y. Acad. Sci. 1995, 774, 82–110.
14. Wang, D.Y.; Bulbrook, R.D.; Sneddon, A.; Hamilton, T. The metabolic clearance rates of dehydroepiandrosterone, testosterone and their sulphate esters in man, rat and rabbit. J. Endocrinol. 1967, 38 (3), 307–318.
15. de Peretti, E.; Forest, M.G. Pattern of plasma dehydroepiandrosterone sulfate levels in humans from birth to adulthood: evidence for testicular production. J. Clin. Endocrinol. Metab. 1978, 47 (3), 572–577.
16. Nestler, J.E., Regulation of human dehydroepiandrosterone metabolism by insulin. Ann. N. Y. Acad. Sci. 1995, 774, 73–81.
17. Legrain, S.; Massien, C.; Lahlou, N.; Roger, M.; Debuire, B.; Diquet, B.; Chatellier, G.; Azizi, M.; Faucounau, V.; Porchet, H.; Forette, F.; Baulieu, E.E. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J. Clin. Endocrinol. Metab. 2000, 85 (9), 3208–3217.
18. Frye, R.F.; Kroboth, P.D.; Kroboth, F.J.; Stone, R.A.; Folan, M.; Salek, F.S.; Pollock, B.G.; Linares, A.M.; Hakala, C., Sex differences in the pharmacokinetics of dehydroepiandrosterone (DHEA) after single- and multiple-dose administration in healthy older adults. J. Clin. Pharmacol 2000, 40 (6), 596–605.
19. Valenti, G.; Banchini, A.; Denti, L.; Maggio, M.; Ceresini, G.; Ceda, G.P. Acute oral administration of dehydroepiandrosterone in male subjects: effect of age on bioavailability, sulfoconjugation and bioconversion in other steroids. J. Endocrinol. Invest. 1999, 22 (Suppl. 10), 24–28.
20. Arlt, W.; Callies, F.; van Vlijmen, J.C.; Koehler, I.; Reincke, M.; Bidlingmaier, M.; Huebler, D.; Oettel, M.; Ernst, M.; Schulte, H.M.; Allolio, B. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N. Engl. J. Med. 1999, 341 (14), 1013–1020.
21. Hunt, P.J.; Gurnell, E.M.; Huppert, F.A.; Richards, C.; Prevost, A.T.; Wass, J.A.; Herbert, J.; Chatterjee, V.K., Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison’s disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab 2000, 85 (12), 4650–4656.
22. Barrett-Connor, E.; Goodman-Gruen, D. The epidemiology of DHEAS and cardiovascular disease. Ann. N. Y. Acad. Sci. 1995, 774, 259–270.
23. Trivedi, D.P.; Khaw, K.T. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J. Clin. Endocrinol. Metab. 2001, 86 (9), 4171–4177.
24. LaCroix, A.Z.; Yano, K.; Reed, D.M. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 1992, 86 (5), 1529–1535.
25. Greendale, G.A.; Edelstein, S.; Barrett-Connor, E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J. Bone Miner. Res. 1997, 12 (11), 1833–1843.
26. Barrett-Connor, E., Lower endogenous androgen levels and dyslipidemia in men with non-insulindependent diabetes mellitus. Ann. Intern. Med 1992, 117 (10), 807–811.
27. Morales, A.J.; Nolan, J.J.; Nelson, J.C.; Yen, S.S., Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab 1994, 78 (6), 1360–1367.
28. Morales, A.J.; Haubrich, R.H.; Hwang, J.Y.; Asakura, H.; Yen, S.S. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin. Endocrinol. (Oxf) 1998, 49 (4), 421–432.
29. Flynn, M.A.; Weaver-Osterholtz, D.; Sharpe- Timms, K.L.; Allen, S.; Krause, G. Dehydroepiandrosterone replacement in aging humans. J. Clin. Endocrinol. Metab. 1999, 84 (5), 1527–1533.
30. Baulieu, E.E.; Thomas, G.; Legrain, S.; Lahlou, N.; Roger, M.; Debuire, B.; Faucounau, V.; Girard, L.; Hervy, M.P.; Latour, F.; Leaud, M.C.; Mokrane, A.; Pitti-Ferrandi, H.; Trivalle, C.; de Lacharriere, O.; Nouveau, S.; Rakoto-Arison, B.; Souberbielle, J.C.; Raison, J.; Le Bouc, Y.; Raynaud, A.; Girerd, X.; Forette, F. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (8), 4279–4284.
31. Labrie, F.; Diamond, P.; Cusan, L.; Gomez, J.L.; Belanger, A.; Candas, B., Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Endocrinol. Metab 1997, 82 (10), 3498–3505.
32. Beer, N.A.; Jakubowicz, D.J.; Matt, D.W.; Beer, R.M.; Nestler, J.E., Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am. J. Med. Sci. 1996, 311 (5), 205–210.
33. Kawano, H.; Yasue, H.; Kitagawa, A.; Hirai, N.; Yoshida, T.; Soejima, H.; Miyamoto, S.; Nakano, M.; Ogawa, H., Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J. Clin. Endocrinol. Metab 2003, 88 (7), 3190–3195.
34. Lasco, A.; Frisina, N.; Morabito, N.; Gaudio, A.; Morini, E.; Trifiletti, A.; Basile, G.; Nicita- Mauro, V.; Cucinotta, D. Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur. J. Endocrinol. 2001, 145 (4), 457–461.
35. Mortola, J.F.; Yen, S.S. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J. Clin. Endocrinol. Metab. 1990, 71 (3), 696–704.
36. Wolkowitz, O.M.; Kramer, J.H.; Reus, V.I.; Costa, M.M.; Yaffe, K.; Walton, P.; Raskind, M.; Peskind, E.; Newhouse, P.; Sack, D.; De Souza, E.; Sadowsky, C.; Roberts, E. DHEA treatment of Alzheimer’s disease: a randomized, doubleblind, placebo-controlled study. Neurology 2003, 60 (7), 1071–1076.
37. Williams, J.R. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune system, and aging. Lipids 2000, 35 (3), 325–331.
38. Nestler, J.E.; Barlascini, C.O.; Clore, J.N.; Blackard, W.G., Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J. Clin. Endocrinol. Metab 1988, 66 (1), 57–61.
39. Johnson, M.D.; Bebb, R.A.; Sirrs, S.M., Uses of DHEA in aging and other disease states. Ageing Res. Rev 2002, 1 (1), 29–41.
40. Davidson, M.; Marwah, A.; Sawchuk, R.J.; Maki, K.; Marwah, P.; Weeks, C.; Lardy, H., Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin. Invest. Med 2000, 23 (5), 300–310.
41. Danenberg, H.D.; Ben-Yehuda, A.; Zakay- Rones, Z.; Gross, D.J.; Friedman, G. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects. J. Clin. Endocrinol. Metab. 1997, 82 (9), 2911–2914.
42. Casson, P.R.; Andersen, R.N.; Herrod, H.G.; Stentz, F.B.; Straughn, A.B.; Abraham, G.E.; Buster, J.E. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am. J. Obstet. Gynecol. 1993, 169 (6), 1536–1539.
43. Kroboth, P.D.; Salek, F.S.; Pittenger, A.L.; Fabian, T.J.; Frye, R.F. DHEA and DHEA-S: a review. J. Clin. Pharmacol. 1999, 39 (4), 327–348.
44. Piketty, C.; Jayle, D.; Leplege, A.; Castiel, P.; Ecosse, E.; Gonzalez-Canali, G.; Sabatier, B.; Boulle, N.; Debuire, B.; Le Bouc, Y.; Baulieu, E.E.; Kazatchkine, M.D. Double-blind placebocontrolled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. Clin. Endocrinol. (Oxf) 2001, 55 (3), 325–330.
45. Rabkin, J.G.; Ferrando, S.J.; Wagner, G.J.; Rabkin, R. DHEA treatment for HIV þ patipatients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology 2000, 25 (1), 53–68.
46. Wolkowitz, O.M.; Reus, V.I.; Keebler, A.; Nelson, N.; Friedland, M.; Brizendine, L.; Roberts, E. Double-blind treatment of major depression with dehydroepiandrosterone. Am. J. Psychiatry 1999, 156 (4), 646–649.
47. Bloch, M.; Schmidt, P.J.; Danaceau, M.A.; Adams, L.F.; Rubinow, D.R. Dehydroepiandrosterone treatment of midlife dysthymia. Biol. Psychiatry 1999, 45 (12), 1533–1541.
48. Wallace, M.B.; Lim, J.; Cutler, A.; Bucci, L. Effects of dehydroepiandrosterone vs. androstenedione supplementation in men. Med. Sci. Sports Exerc. 1999, 31 (12), 1788–1792.
49. Brown, G.A.; Vukovich, M.D.; Sharp, R.L.; Reifenrath, T.A.; Parsons, K.A.; King, D.S., Effect of oral DHEA on serum testosterone and adaptations to resistance training in young men. J. Appl. Physiol 1999, 87 (6), 2274–2283.
50. Parasrampuria, J.; Schwartz, K.; Petesch, R. Quality control of dehydroepiandrosterone dietary supplement products. J. Am. Med. Assoc. 1998, 280 (18), 1565.
51. Dyner, T.S.; Lang, W.; Geaga, J.; Golub, A.; Stites, D.; Winger, E.; Galmarini, M.; Masterson, J.; Jacobson, M.A., An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV disease. J. Acquir. Immune Defic. Syndr 1993, 6 (5), 459–465.
52. Genazzani, A.D.; Stomati, M.; Strucchi, C.; Puccetti, S.; Luisi, S.; Genazzani, A.R. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulinlike growth factor-1 secretion in early and late postmenopausal women. Fertil. Steril. 2001, 76 (2), 241–248.
53. Salek, F.S.; Bigos, K.L.; Kroboth, P.D. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies. J. Clin. Pharmacol. 2002, 42 (3), 247–266.